Avidity Biosciences Inc
Research Avidity Biosciences Inc (RNA) on Bullrun: market cap USD 140.44M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerRNA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 140.44M
- Financial periodQ2 2026
- RevenueUSD 3.00M
- Net income-USD 20.19M
- Free cash flow-USD 3.96M
Valuation Snapshot
latest market cap is USD 140.44M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 18.62M | -USD 76.68M | -USD 42.57M | n/a | -2.89 | USD 270.00M | USD 3.67M | USD 207.29M |
| FY2024 | USD 10.90M | -USD 25.12M | -USD 22.82M | n/a | -1.47 | USD 219.87M | USD 6.80M | -USD 61.11M |
| FY2023 | USD 9.76M | -USD 6.39M | USD 56.07M | n/a | -0.37 | USD 185.08M | USD 9.85M | -USD 70.62M |
| FY2022 | USD 9.22M | -USD 174.00M | -USD 139.09M | n/a | -3.34 | USD 340.40M | USD 10.69M | USD 578.08M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 140.44M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 10.87B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 3.49B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 716.55M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 1.51B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.14B | n/a | n/a | n/a |
About Avidity Biosciences Inc
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Avidity Biosciences Inc's market cap?
Avidity Biosciences Inc's market capitalization is USD 140.44M.
What does Avidity Biosciences Inc do?
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases.